Neuroinflammation in ischemic brain injury as an adaptive process

Medical Hypotheses

Volumn 82, Issue 2, 2014, Pages 151-158

  Rivers Auty, Jack ^a   Ashton, John C ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; NEUROPROTECTIVE AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; STEROID;

ADAPTIVE IMMUNITY; AGE; ARTICLE; BRAIN INJURY; BRAIN ISCHEMIA; HUMAN; NERVOUS SYSTEM INFLAMMATION; NONHUMAN;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BRAIN INJURIES; BRAIN ISCHEMIA; HUMANS; INFLAMMATION; MICROGLIA; MODELS, THEORETICAL; NEUROPROTECTIVE AGENTS; NITRIC OXIDE; SIGNAL TRANSDUCTION;

EID: 84892366896     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.024     Document Type: Article

References (111)

1. Rivers J.R., Ashton J.C. The development of cannabinoid CBII receptor agonists for the treatment of central neuropathies. Cent Nerv Syst Agents Med Chem 2010, 10:47-64.
2. Nishizawa Y. Glutamate release and neuronal damage in ischemia. Life Sci 2001, 69:369-381.
3. Rothman S.M., Olney J.W. Excitotoxicity and the NMDA receptor. Trends Neurosci 1987, 10:299-302.
4. Gitto E., Pellegrino S., Gitto P., Barberi I., Reiter R.J. Oxidative stress of the newborn in the pre- and postnatal period and the clinical utility of melatonin. J Pineal Res 2009, 46:128-139.
5. Ikonomidou C., Kaindl A.M. Neuronal death and oxidative stress in the developing brain. Antioxid Redox Signal 2011, 14:1535-1550.
6. Valko M., Leibfritz D., Moncol J., Cronin M.T.D., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007, 39:44-84.
7. Shah I.M., Macrae I.M., Di Napoli M. Neuroinflammation and neuroprotective strategies in acute ischaemic stroke - from bench to bedside. Curr Mol Med 2009, 9:336-354.
8. Hu X.M., Li P.Y., Guo Y.L., Wang H.Y., Leak R.K., Chen S.E., et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke 2012, 43:3063-U3474.
9. Chao C.C., Hu S., Molitor T.W., Shaskan E.G., Peterson P.K. Activated microglia mediate neuronal cell injury via a nitric oxide mechanism. J Immunol 1992, 149:2736-2741.
10. Gehrmann J., Matsumoto Y., Kreutzberg G.W. Microglia - intrinsic immuneffector cell of the brain. Brain Res Rev 1995, 20:269-287.
11. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
12. Melchior B., Puntambekar S.S., Carson M.J. Microglia and the control of autoreactive T cell responses. Neurochem Int 2006, 49:145-153.
13. Nimmerjahn A., Kirchhoff F., Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308:1314-1318.
14. Dinarello C.A. Inflammatory cytokines - interleukin-1 and tumor-necrosis-factor as effector molecules in autoimmune-diseases. Curr Opin Immunol 1991, 3:941-948.
15. Gebicke-Haerter P.J. Microglia in neurodegeneration: molecular aspects. Microsc Res Tech 2001, 54:47-58.
16. Goodman & Gilman's the pharmacological basis of therapeutics 2011, McGraw-Hill, New York, USA. 12th ed. L.L. Brunton, D.K. Blumenthal, N. Murri, R.H. Dandan, B.C. Knollmann (Eds.).
17. Andersson J., Bjork L., Dinarello C.A., Towbin H., Andersson U. Lipopolysaccharide induces human interleukin-1 receptor antagonist and interleukin-1 production in the same cell. Eur J Immunol 1992, 22:2617-2623.
18. Clarkson A.N., Liu H.Z., Pearson L., Kapoor M., Harrison J.C., Sammut I.A., et al. Neuroprotective effects of spermine following hypoxia-ischemia-induced brain damage: a mechanistic study. FASEB J 2004, 18:1114-1135.
19. Clarkson A.N., Liu H.Z., Rahman R., Jackson D.M., Appleton I., Kerr D.S. Clomethiazole: mechanisms underlying lasting neuroprotection after hypoxia-ischemia. FASEB J 2005, 19:1036-1060.
20. Kaushal V., Schlichter L.C. Mechanisms of microglia-mediated neurotoxicity in a new model of the stroke penumbra. J Neurosci 2008, 28:2221-2230.
21. Sutherland B.A., Shaw O.M., Clarkson A.N., Jackson D.M., Sammut I.A., Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate after hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 2004, 18:258-280.
22. Cai Z., Lin S., Fan L.W., Pang Y., Rhodes P.G. Minocycline alleviates hypoxic-ischemic injury to developing oligodendrocytes in the neonatal rat brain. Neuroscience 2006, 137:425-435.
23. Cai Z.W., Pang Y., Xiao F., Rhodes P.G. Chronic ischemia preferentially causes white matter injury in the neonatal rat brain. Brain Res 2001, 898:126-135.
24. Jin Y.X., Silverman A.J., Vannucci S.J. Mast cells are early responders after hypoxia-ischemia in immature rat brain. Stroke 2009, 40:3107-3112.
25. Fan L.W., Lin S.Y., Pang Y., Rhodes P.G., Cai Z.W. Minocycline attenuates hypoxia-ischemia-induced neurological dysfunction and brain injury in the juvenile rat. Eur J Neurosci 2006, 24:341-350.
26. Patten B., Mendell J, Bruun B., Curtin W., Carter S. Double blind study of the effects of dexamethasone on acute stroke. Steroids and Brain Edema 1972, 259-266. Springer Berlin Heidelberg. H.J. Reulen, K. Schürmann (Eds.).
27. Williams G.C., Nesse R.M. The dawn of Darwinian medicine. Q Rev Biol 1991, 66:1-22.
28. Lo E.H. A new penumbra: transitioning from injury into repair after stroke. Nat Med 2008, 14:497-500.
29. Moskowitz M.A., Lo E.H., Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron 2010, 67:181-198.
30. Zhu D.Y., Liu S.H., Sun H.S., Lu Y.M. Expression of inducible nitric oxide synthase after focal cerebral ischemia stimulates neurogenesis in the adult rodent dentate gyrus. J Neurosci 2003, 23:223-229.
31. Lee J.C., Cho G.S., Kim H.J., Lim J.H., Oh Y.K., Nam W., et al. Accelerated cerebral ischemic injury by activated macrophages/microglia after lipopolysaccharide microinjection into rat corpus callosum. Glia 2005, 50:168-181.
32. Frenkel D., Huang Z.H., Maron R., Koldzic D.N., Moskowitz M.A., Weiner H.L. Neuroprotection by IL-10-producing MOG CD4+T cells following ischemic stroke. J Neurol Sci 2005, 233:125-132.
33. Ooboshi H., Ibayashi S., Shichita T., Kumai Y., Takada J., Ago T., et al. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 2005, 111:913-919.
34. Matsukawa N., Yasuhara T., Hara K., Xu L., Maki M., Yu G.L., et al. Therapeutic targets and limits of minocycline neuroprotection in experimental ischemic stroke. BMC Neurosci 2009, 10:126-142.
35. Goericke S.L., Engelhorn T., Forsting M., Speck U., Maderwald S., Ladd M.E., et al. Intrathecal corticoids in permanent focal cerebral ischemia in rats. Part I: a new therapeutic approach in the acute phase. J Cereb Blood Flow Metab 2010, 30:801-807.
36. Carty M.L., Wixey J.A., Reinebrant H.E., Gobe G., Colditz P.B., Buller K.M. Ibuprofen inhibits neuroinflammation and attenuates white matter damage following hypoxia-ischemia in the immature rodent brain. Brain Res 2011, 1402:9-19.
37. Jiang T., Gao L., Guo J., Lu J., Wang Y., Zhang Y. Suppressing inflammation by inhibiting the NF-kappa B pathway contributes to the neuroprotective effect of angiotensin-(1-7) in rats with permanent cerebral ischaemia. Br J Pharmacol 2012, 167:1520-1532.
38. Li S., Zhang X., Wang Y., Ji H., Du Y., Liu H. DAPT protects brain against cerebral ischemia by down-regulating the expression of Notch 1 and nuclear factor kappa B in rats. Neurol Sci 2012, 33:1257-1264.
39. Seifert H.A., Leonardo C.C., Hall A.A., Rowe D.D., Collier L.A., Benkovic S.A., et al. The spleen contributes to stroke induced neurodegeneration through interferon gamma signaling. Metab Brain Dis 2012, 27:131-141.
40. Wideroe M., Havnes M.B., Morken T.S., Skranes J., Goa P.E., Brubakk A.M. Doxycycline treatment in a neonatal rat model of hypoxia-ischemia reduces cerebral tissue and white matter injury: a longitudinal magnetic resonance imaging study. Eur J Neurosci 2012, 36:2006-2016.
41. Raza S.S., Khan M.M., Ahmad A., Ashafaq M., Islam F., Wagner W.P., et al. Neuroprotective effect of naringenin is mediated through suppression of NF-kappaB signaling pathway in experimental stroke. Neuroscience 2013, 230:157-171.
42. Shao J., Liu T., Xie Q.R., Zhang T., Yu H., Wang B., et al. Adjudin attenuates lipopolysaccharide (LPS)- and ischemia-induced microglial activation. J Neuroimmunol 2013, 254:83-90.
43. Beamer N.B., Coull B.M., Clark W.M., Hazel J.S., Silberger J.R. Ineterleuki-6 and interleukin-1 receptor antagonish in acute stroke. Ann Neurol 1995, 37:800-805.
44. Schori H., Yoles E., Schwartz M. T-cell-based immunity counteracts the potential toxicity of glutamate in the central nervous system. J Neuroimmunol 2001, 119:199-204.
45. Schwartz M., Moalem G. Beneficial immune activity after CNS injury: prospects for vaccination. J Neuroimmunol 2001, 113:185-192.
46. Frenkel D., Huang Z., Maron R., Koldzic D.N., Moskowitz M.A., Weiner H.L. Neuroprotection by IL-10-producing MOG CD4+ T cells following ischemic stroke. J Neurol Sci 2005, 233:125-132.
47. Kriz J., Lalancette-Hebert M. Inflammation, plasticity and real-time imaging after cerebral ischemia. Acta Neuropathol (Berl) 2009, 117:497-509.
48. Sasaki T., Kitagawa K., Sugiura S., Omura-Matsuoka E., Tanaka S., Yagita Y., et al. Implication of cyclooxygenase-2 on enhanced proliferation of neural progenitor cells in the adult mouse hippocampus after ischemia. J Neurosci Res 2003, 72:461-471.
49. Islam O., Gong X.D., Rose-John S., Heese K. Interleukin-6 and neural stem cells: more than gliogenesis. Mol Biol Cell 2009, 20:188-199.
50. Stefano G.B., Liu Y., Goligorsky M.S. Cannabinoid receptors are coupled to nitric oxide release in invertebrate immunocytes, microglia, and human monocytes. J Biol Chem 1996, 271:19238-19242.
51. Dawkins R. The extended phenotype: the gene as the unit of selection 1982, Freeman, Oxford Oxfordshire, San Francisco.
52. Kappelman J. The evolution of body mass and relative brain size in fossil hominids. J Hum Evol 1996, 30:243-276.
53. Manual of stroke models in rats 2009, CRC Press, Boca Raton. Y. Wang-Fischer (Ed.).
54. Jablonka J.A., Witte O.W., Kossut M. Photothrombotic infarct impairs experience-dependent plasticity in neighboring cortex. Neuroreport 2007, 18:165-169.
55. Wittman A.B., Wall L.L. The evolutionary origins of obstructed labor: bipedalism, encephalization, and the human obstetric dilemma. Obstet Gynecol Surv 2007, 62:739-748.
56. Medawar P.B. An unsolved problem of biology: an inaugural lecture delivered at University College, London, 6 December, 1951 1952, H.K. Lewis and Company.
57. Ashcroft G.S., Horan M.A., Ferguson M.W.J. The effects of ageing on wound healing: immunolocalisation of growth factors and their receptors in a murine incisional model. J Anat 1997, 190:351-365.
58. Brucker M.J., Gruskin E., Farrell C.L., Siddiqui A., Mustoe T.A. Differential expression of platelet-derived growth factor receptor-beta in an aging model of wound repair. Wound Repair Regen 1996, 4:219-223.
59. Lyng K., Munkeby B.H., Saugstad O.D., Stray-Pedersen B., Froen J.F. Effect of interleukin-10 on newborn piglet brain following hypoxia-ischemia and endotoxin-induced inflammation. Biol Neonate 2005, 87:207-216.
60. Boutin H., LeFeuvre R.A., Horai R., Asano M., Iwakura Y., Rothwell N.J. Role of IL-1 alpha and IL-1 beta in ischemic brain damage. J Neurosci 2001, 21:5528-5534.
61. Touzani O., Boutin H., LeFeuvre R., Parker L., Miller A., Luheshi G., et al. Interleukin-1 influences ischemic brain damage in the mouse independently of the interleukin-1 type I receptor. J Neurosci 2002, 22:38-43.
62. Xiong X.X., Barreto G.E., Xu L.J., Ouyang Y.B., Xie X.M., Giffard R.G. Increased brain injury and worsened neurological outcome in interleukin-4 knockout mice after transient focal cerebral ischemia. Stroke 2011, 42:2026-2032.
63. Clark W.M., Rinker L.G., Lessov N.S., Hazel K., Hill J.K., Stenzel-Poore M., et al. Lack of interleukin-6 expression is not protective against focal central nervous system ischemia. Stroke 2000, 31:1715-1720.
64. Iadecola C., Sugimoto K., Niwa K., Kazama K., Ross M.E. Increased susceptibility to ischemic brain injury in cyclooxygenase-1-deficient mice. J Cereb Blood Flow Metab 2001, 21:1436-1441.
65. Hu W.W., Fan Y.Y., Shen Y., Yang Y.Z., Dai H.B., Fu Q., et al. Mast cell-derived mediators protect against oxygen-glucose deprivation-induced injury in PC12 cells and neurons. Neurosci Lett 2007, 423:35-40.
66. Justicia C., Panes J., Sole S., Cervera A., Deulofeu R., Chamorro A., et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003, 23:1430-1440.
67. Liesz A., Suri-Payer E., Veltkamp C., Doerr H., Sommer C., Rivest S., et al. Regulatory T cells are key cerebroprotective immunomodulators in acute experimental stroke. Nat Med 2009, 15:192-199.
68. Shaked I., Porat Z., Gersner R., Kipnis J., Schwartz M. Early activation of microglia as antigen-presenting cells correlates with T cell-mediated protection and repair of the injured central nervous system. J Neuroimmunol 2004, 146:84-93.
69. Vila N., Castillo J., Davalos A., Esteve A., Planas A.M., Chamorro A. Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke 2003, 34:671-675.
70. Tischner D., Reichardt H.M. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol 2007, 275:62-70.
71. Tuor U.I. Glucocorticoids and the prevention of hypoxic-ischemic brain damage. Neurosci Biobehav Rev 1997, 21:175-179.
72. Gelderblom M., Leypoldt F., Steinbach K., Behrens D., Choe C.U., Siler D.A., et al. Temporal and spatial dynamics of cerebral immune cell accumulation in stroke. Stroke 2009, 40:1849-1857.
73. LeBlanc M.H., Qian X.B., Cai Z.W. The effect of glucose during ischemia on brain ATP, lactate, and glutamate in piglets. Biol Neonate 1997, 72:243-254.
74. Groeneweg F.L., Karst H., de Kloet E.R., Joels M. Mineralocorticoid and glucocorticoid receptors at the neuronal membrane, regulators of nongenomic corticosteroid signalling. Mol Cell Endocrinol 2012, 350:299-309.
75. Sandercock P.A.G., Soane T. Corticosteroids for acute ischaemic stroke 2011, Cochrane Database Syst Rev.
76. Edwards P., Arango M., Balica L., Cottingham R., El-Sayed H., Farrell B., et al. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury - outcomes at 6months. Lancet 2005, 365:1957-1959.
77. Burch D. Taking the medicine 2009, Chatto & Windus, Great Britain.
78. Leroux P., Hennebert C., Catteau J., Legros H., Hennebert O., Laudenbach V., et al. Neuroprotective effects vary across nonsteroidal antiinflammatory drugs in a mouse model of developing excitotoxic brain injury. Neuroscience 2010, 167:716-723.
79. Jantzie L.L., Cheung P.Y., Todd K.G. Doxycycline reduces cleaved caspase-3 and microglial activation in an animal model of neonatal hypoxia-ischemia. J Cereb Blood Flow Metab 2005, 25:314-324.
80. Nikodemova M., Duncan I.D., Watters J.J. Minocycline exerts inhibitory effects on multiple mitogen-activated protein kinases and I kappa B alpha degradation in a stimulus-specific manner in microglia. J Neurochem 2006, 96:314-323.
81. Nikodemova M., Jackson S.J., Duncan I.D. The effect of minocycline on MHC II expression in microglia. J Neurochem 2006, 96:45.
82. Kernt M., Neubauer A.S., Eibl K.H., Wolf A., Ulbig M.W., Kampik A., et al. Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol 2010, 4:591-604.
83. Tang C.M., Hwang C.S., Chen S.D., Yang D.I. Neuroprotective mechanisms of minocycline against sphingomyelinase/ceramide toxicity: roles of Bcl-2 and thioredoxin. Free Radic Biol Med 2011, 50:710-721.
84. Tang X.N., Wang Q., Koike M.A., Cheng D., Goris M.L., Blankenberg F.G., et al. Monitoring the protective effects of minocycline treatment with radiolabeled annexin V in an experimental model of focal cerebral ischemia. J Nucl Med 2007, 48:1822-1828.
85. Tang M.N., Wang Q., Koikel M.A., Cheng D., Goris M.L., Blankenberg F.G., et al. Monitoring the protective effects of minocycline treatment with radiolabeled annexin v in an experimental model of focal cerebral ischemia. J Nucl Med 2007, 48:1822-1828.
86. Ma L., Zhu Z.H., Zhao Y., Hou L.H., Wang Q., Xiong L.Z., et al. Cannabinoid receptor type 2 activation yields delayed tolerance to focal cerebral ischemia. Curr Neurovasc Res 2011, 8:145-152.
87. Zhang M., Martin B.R., Adler M.W., Razdan R.K., Jallo J.I., Tuma R.F. Cannabinoid CB2 receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 2007, 27:1387-1396.
88. Gifford A.N., Makriyannis A., Volkow N.D., Gatley S.J. In vivo imaging of the brain cannabinoid receptor. Chem Phys Lipids 2002, 121:65-72.
89. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and Delta(9)-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998, 95:8268-8273.
90. Hampson A.J., Grimaldi M., Axelrod J., Wink D. Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998, 95:8268-8273.
91. Li C., Bowe J.E., Huang G.C., Amiel S.A., Jones P.M., Persaud S.J. Cannabinoid receptor agonists and antagonists stimulate insulin secretion from isolated human islets of Langerhans. Diabetes Obes Metab 2011, 13:903-910.
92. De Petrocellis L., Orlando P., Moriello A.S., Aviello G., Stott C., Izzo A.A., et al. Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation. Acta Physiol 2012, 204:255-266.
93. McDougall J.J., Yu V., Thomson J. In vivo effects of CB2 receptor-selective cannabinoids on the vasculature of normal and arthritic rat knee joints. Br J Pharmacol 2008, 153:358-366.
94. Pegorini S., Zani A., Braida D., Guerini-Rocco C., Sala M. Vanilloid VR1 receptor is involved in rimonabant-induced neuroprotection. Br J Pharmacol 2006, 147:552-559.
95. Ralevic V., Kendall D.A., Jerman J.C., Middlemiss D.N., Smart D. Cannabinoid activation of recombinant and endogenous vanilloid receptors. Eur J Pharmacol 2001, 424:211-219.
96. Schuelert N., Zhang C., Mogg A.J., Broad L.M., Hepburn D.L., Nisenbaum E.S., et al. Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain. Osteoarthritis Cartilage 2010, 18:1536-1543.
97. Sharif-Naeini R., Ciura S., Bourque C.W. TRPV1 gene required for thermosensory transduction and anticipatory secretion from vasopressin neurons during hyperthermia. Neuron 2008, 58:179-185.
98. Muzzi M., Felici R., Cavone L., Gerace E., Minassi A., Appendino G., et al. Ischemic neuroprotection by TRPV1 receptor-induced hypothermia. J Cereb Blood Flow Metab 2012, 32:978-982.
99. Zarruk J.G., Fernandez-Lopez D., Garcia-Yebenes I., Garcia-Gutierrez M.S., Vivancos J., Nombela F., et al. Cannabinoid type 2 receptor activation downregulates stroke-induced classic and alternative brain macrophage/microglial activation concomitant to neuroprotection. Stroke 2012, 43:211-218.
100. Golech S.A., McCarron R.M., Chen Y., Bembry J., Lenz F., Mechoulam R., et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Mol Brain Res 2004, 132:87-92.
101. Wagner J.A., Abesser M., Karcher J., Laser M., Kunos G. Coronary vasodilator effects of endogenous cannabinoids in vasopressin-preconstricted unpaced rat isolated hearts. J Cardiovasc Pharmacol 2005, 46:348-355.
102. Zhang M., Martin B.R., Adler M.W., Razdan R.K., Jallo J.I., Tuma R.F. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 2007, 27:1387-1396.
103. Altman D.I., Young R.S., Yagel S.K. Effects of dexamethasone in hypoxic-ischemic brain injury in the neonatal rat. Biol Neonate 1984, 46:149-156.
104. Klehmet J., Harms H., Richter M., Prass K., Volk H.D., Dirnagl U., et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. Neuroscience 2009, 158:1184-1193.
105. Macleod M.R., van der Worp H.B., Sena E.S., Howells D.W., Dirnagl U., Donnan G.A. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008, 39:2824-2829.
106. Freeman B.D., Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs 2000, 9:1651-1663.
107. Rivers-Auty J, Bhatia M. Hydrogen sulfide, systemic inflammatory response syndrome (SIRS) and compensatory anti-inflammatory response syndrome (CARS) following sepsis. OA, Inflammation 2013; 01: 2.
108. Milligan E.D., Watkins L.R. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 2009, 10:23-36.
109. Milligan E.D., Sloane E.M., Watkins L.R. Glia in pathological pain: a role for fractalkine. J Neuroimmunol 2008, 198:113-120.
110. Silver J., Miller J.H. Regeneration beyond the glial scar. Nat Rev Neurosci 2004, 5:146-156.
111. Takeuchi N., Izumi S.I. Maladaptive plasticity for motor recovery after stroke: mechanisms and approaches. Neural Plast 2012, 10.1155/2012/359728.